10-Q: Bioventus Returns to Profit, Secures New Debt Facility

Bioventus Inc. reported a significant return to net income in Q2 2025, driven by strategic divestitures and new product clearances, despite a slight decline in overall net sales.

Summary

• Bioventus Inc. reported net income of $9.272 million for the three months ended June 28, 2025, a substantial improvement from a net loss of $34.217 million in the prior year period.
• For the six months ended June 28, 2025, net income was $5.950 million, compared to a net loss of $40.598 million in the same period last year.
• Basic and diluted earnings per share (EPS) for Class A common stock improved to $0.11 for the three-month period and $0.07 for the six-month period, up from losses of $0.40 and $0.48, respectively.
• Net sales for the three months ended June 28, 2025, were $147.660 million, a 2.4% decrease from $151.217 million in the prior year.
• Net sales for the six months ended June 28, 2025, were $271.536 million, a 3.3% decrease from $280.674 million in the prior year.
• Adjusted EBITDA for the three months ended June 28, 2025, was $33.751 million, a slight decrease from $34.452 million in the prior year.
• Adjusted EBITDA for the six months ended June 28, 2025, was $52.963 million, down from $57.075 million in the prior year.
• The company entered into a new Credit Agreement on July 31, 2025, consisting of a $300 million term loan and a $100 million revolving credit facility, expected to provide $2.0 million in annual interest expense savings and extend debt maturity to July 2030.
• FDA 510(k) clearances were received in July 2025 for TalisMann and StimTrial, expanding the Peripheral Nerve Stimulation (PNS) portfolio for chronic pain management.
• The sale of the Advanced Rehabilitation Business, closed on December 31, 2024, generated $24.7 million (net of fees), with proceeds used to pay down $20.0 million in long-term debt; potential earn-out payments of $20.0 million are possible based on 2025 and 2026 fiscal year sales.
• The company paid $19.771 million in contingent consideration related to the Bioness acquisition during the first half of 2025, fully settling this liability.
• Net cash from operating activities decreased by $2.6 million to $6.607 million for the six months ended June 28, 2025, compared to the prior year.

Sentiment

Score: 7

Explanation: The company's return to profitability and successful debt refinancing are strong positives, indicating improved financial health and stability. Key FDA clearances for new products in a growing market segment (PNS) provide a clear path for future growth. While net sales declined and cash from operations decreased, these are partly attributable to strategic divestitures aimed at focusing on core, higher-potential businesses. Ongoing legal proceedings remain a concern, but the overall strategic and financial trajectory appears positive.

Positives

• Achieved net income of $9.272 million for Q2 2025 and $5.950 million for H1 2025, a significant turnaround from prior year losses.
• Secured a new 2025 Credit Agreement, expected to yield $2.0 million in annual interest expense savings, increase liquidity, and extend debt maturity to July 2030.
• Received FDA 510(k) clearances for TalisMann and StimTrial in July 2025, expanding the innovative Peripheral Nerve Stimulation (PNS) portfolio for chronic pain management.
• Successfully divested the non-core Advanced Rehabilitation Business, generating $24.7 million in proceeds used for debt reduction, with potential for an additional $20.0 million in earn-out payments.
• Settled the Ciarciello class action lawsuit for $15.3 million, with claims dismissed and no admission of liability.
• International segment demonstrated strong Adjusted EBITDA growth of 84.3% for the three-month period and 29.7% for the six-month period.
• Surgical Solutions segment experienced volume growth in both U.S. and International markets.
• Sales of the EXOGEN Bone Stimulation System increased by $1.7 million for the three-month period and $3.0 million for the six-month period in the U.S.

Negatives

• Overall net sales decreased by 2.4% for the three-month period and 3.3% for the six-month period compared to the prior year.
• Adjusted EBITDA slightly decreased by 2.0% for the three-month period and 7.2% for the six-month period.
• Net cash from operating activities decreased by $2.550 million to $6.607 million for the six months ended June 28, 2025.
• Net cash from investing activities showed a larger outflow of $2.195 million for the six months ended June 28, 2025, compared to $1.077 million in the prior year.
• Net cash from financing activities resulted in a larger outflow of $13.716 million for the six months ended June 28, 2025, partly due to a $19.771 million contingent consideration payment.
• U.S. Pain Treatments sales decreased due to lower average selling prices (ASP) and lower private payer rebates.
• Restorative Therapies sales significantly declined by 32.2% in the U.S. and 27.3% internationally for the three-month period, primarily due to the Advanced Rehabilitation Business divestiture.
• Multiple derivative shareholder lawsuits remain ongoing, requiring continued legal attention and potential costs, despite the company's belief that claims lack merit.

Risks

• Failure to realize expected benefits from the divestiture of the Advanced Rehabilitation Business or the new 2025 Credit Agreement.
• The FDA regulatory process is expensive, time-consuming, and uncertain, and failure to obtain and maintain required regulatory clearances and approvals could prevent commercialization of products.
• Inability to successfully commercialize newly developed or acquired products or therapies within expected timeframes.
• Clinical studies of future product candidates may not produce results necessary to support regulatory clearance or approval.
• Failure to properly manage growth or scale business processes, systems, or data management could adversely affect the business.
• Inability to attract, retain, and motivate senior management and highly qualified personnel necessary to execute strategic plans.
• Issues with the supply of products or components due to product quality, regulatory compliance, increased costs, disruptions, shortages, contamination, or mislabeling.
• Risk of not meeting certain debt covenants under the 2025 Credit Agreement, potentially requiring accelerated repayment of indebtedness.
• Restrictions on operations and other costs associated with indebtedness.
• Requirement for additional capital to fund current financial obligations and support business growth.
• Failure to establish and maintain effective financial controls could adversely affect the business and stock price.
• Inability to complete acquisitions or successfully integrate new businesses, products, or technologies cost-effectively and non-disruptively.
• Cash maintained at financial institutions often exceeds federally insured limits, posing a risk.
• Exposure to securities class action litigation and other litigation in the future, requiring significant management time, legal expenses, and potentially unfavorable outcomes.
• High dependence on a limited number of products.
• Long-term growth depends on the ability to develop, acquire, and commercialize new products, line extensions, or expanded indications.
• Demand for products depends on continued and future acceptance by physicians, patients, and third-party payers.
• Proposed down classification of non-invasive bone growth stimulators (e.g., EXOGEN) by the FDA could increase future competition and adversely affect sales.
• Failure to achieve and maintain adequate levels of coverage and/or reimbursement for products or procedures using products (e.g., hyaluronic acid viscosupplements).
• Competitive factors, including pricing, from other companies with longer operating histories, more established products, or greater resources.
• Governments outside the United States might not provide coverage or reimbursement of products.
• Reclassification of HA products from medical devices to drugs by the FDA could negatively impact marketing and require costly additional clinical studies.
• Failure to properly manage anticipated growth and strengthen brands.
• Risks related to product liability claims.
• Fluctuations in demand for products.
• Reliance on a limited number of third-party manufacturers.
• Damage or inoperability of facilities could prevent research, development, and manufacturing.
• Economic, political, regulatory, and other risks related to international sales, manufacturing, and operations.
• Failure to maintain contractual relationships.
• Security breaches, unauthorized access, disclosure of information, cyberattacks, or other incidents, or the perception that confidential information is not secure.
• Failure of key information technology and communications systems, processes, or sites.
• Risks related to future capital needs.
• Failure to comply with extensive governmental regulation relevant to the company and its products.
• Subject to enforcement action if engaging in improper claims submission practices, and resulting audits or denials could reduce net sales or profits.
• Unstable political or economic conditions.
• Legislative or regulatory reforms.
• Adverse impacts due to public health outbreaks.
• Intellectual property matters.
• Dilution of Class A common stockholders upon an exchange of outstanding common membership interests in BV LLC could adversely affect the market price of Class A common stock.
• International tariffs, including those applied to goods traded between the United States and other countries, and restrictions on imported goods, may adversely affect business.

Future Outlook

The company expects to begin a limited commercial release of its newly FDA-cleared Peripheral Nerve Stimulation (PNS) solutions, TalisMann and StimTrial, in select U.S. markets during the third quarter of 2025, with a broader rollout planned for early 2026. It anticipates potential earn-out payments of up to $20.0 million from the Advanced Rehabilitation Business divestiture based on 2025 and 2026 fiscal year sales. The company plans to obtain future funding through additional equity financings, indebtedness, or a combination, and may explore further divestiture opportunities for non-core assets to enhance liquidity. The recently enacted 'One Big Beautiful Bill Act' (OBBBA) tax legislation, effective Q3 2025, is not expected to materially impact financial statements. The company does not anticipate the restrictions within the new 2025 Credit Agreement to affect or limit its ability to conduct business in the ordinary course.

Management Comments

• We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically proven solutions.
• The 2025 Credit Agreement is expected to provide $2.0 million of annual interest expense savings, increased liquidity and debt maturity extension to July 2030.
• These clearances mark an important step forward and represent a substantial growth opportunity as we look to expand in the PNS market.
• With TalisMann and StimTrial now FDA-cleared, we offer a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility.
• This development also reinforces our commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs.
• TalisMann combines our patented electric field conduction technology with an integrated pulse generator to potentially reach deeper, larger nerves. This combination is designed to provide long-term relief from chronic nerve pain for patients, potentially increasing the number of patients who respond to neuromodulation therapy. From a physician's perspective, the increase in power allows for easier lead placement and potentially broadens addressable nerves.
• StimTrial provides physicians the ability to evaluate patient response to PNS therapy, which we expect will facilitate physician adoption and payer reimbursement where trial assessments are required.
• The Advanced Rehabilitation Business was considered non-core and required additional research and development expenditures to achieve its next stage of growth.
• We believe the claims alleged in the above derivative matters lack merit and intends to defend itself vigorously.
• We were in compliance with the financial covenants as stated in the Amended 2019 Credit Agreement as of June 28, 2025.
• The Company does not expect any of these restrictions [in 2025 Credit Agreement] to affect or limit its ability to conduct business in the ordinary course.

Industry Context

Bioventus operates within the dynamic global medical device industry, specifically targeting musculoskeletal health, pain management, and surgical solutions. The company's focus on non-opioid, minimally invasive therapies, particularly with the expansion into the Peripheral Nerve Stimulation (PNS) market, aligns with broader healthcare trends emphasizing patient-centric, less invasive treatments for chronic conditions. The divestiture of its Advanced Rehabilitation Business reflects a strategic move common in the industry to streamline portfolios, shed non-core assets, and focus resources on higher-growth or more profitable segments. The successful refinancing of its debt through the new 2025 Credit Agreement demonstrates an effort to optimize capital structure and enhance financial flexibility, a critical aspect for medical device companies requiring significant R&D and market development investments.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The class action lawsuit Ciarciello v. Bioventus Inc. was settled for $15.3 million, with final court approval on December 18, 2024, and all claims dismissed without admission of liability. The company incurred $0.04 million in related costs during the six months ended June 28, 2025.
• Multiple derivative shareholder lawsuits (Grogan, Sanderson, Vince, Hyung) have been filed against current and former directors and officers, alleging similar misconduct as the Ciarciello case (violations of Exchange Act, breaches of fiduciary duties, etc.).
• The Grogan and Sanderson cases have been consolidated and stayed pending settlement discussions, with status updates requested by the court.
• The Vince case was voluntarily dismissed by the plaintiff and refiled in Delaware Chancery Court, where a motion to dismiss has been filed by defendants.
• The Hyung case was transferred to the District of Delaware, and an amended complaint was filed, with the company believing the claims lack merit and intending to defend vigorously. The outcome of these derivative matters is not presently determinable, and any loss is neither probable nor reasonably estimable.

Related Party Transactions

• The company has a Tax Receivable Agreement (TRA) with Smith & Nephew, Inc. (the Continuing LLC Owner), which provides for payments of 85% of tax benefits realized from increases in the tax basis of BV LLC assets resulting from LLC Interest redemptions or exchanges. As of June 28, 2025, no LLC Interests had been exchanged, and no liabilities under the TRA were recorded.
• Smith & Nephew, Inc. (the Continuing LLC Owner) held 19.1% of the LLC Interests in BV LLC as of June 28, 2025.

Stakeholder Impact

• **Shareholders**: Experienced a significant improvement in net income and EPS, which is positive. However, potential future equity financings could lead to dilution of existing Class A common stockholders. The exchange of LLC Interests by the Continuing LLC Owner could also cause dilution.
• **Employees**: The company had approximately 950 employees as of June 28, 2025. Compensation-related costs decreased due to lower sales and the divestiture of the Advanced Rehabilitation Business. Equity-based compensation plans are in place to incentivize personnel.
• **Customers/Physicians**: The FDA clearances for new Peripheral Nerve Stimulation (PNS) products (TalisMann and StimTrial) offer expanded, non-opioid, minimally invasive treatment options for chronic pain management, potentially benefiting patients and providing physicians with greater flexibility.
• **Creditors**: The new 2025 Credit Agreement extends debt maturity to July 2030 and is expected to reduce annual interest expense, improving the company's ability to service its debt obligations. The company was in compliance with financial covenants as of June 28, 2025.
• **Suppliers**: The company remains subject to annual minimum purchase requirements for certain osteoarthritis (OA) products and relies on a limited number of third-party manufacturers, which poses a supply risk.

Next Steps

• Begin limited commercial release of TalisMann and StimTrial in select U.S. markets during the third quarter of 2025.
• Plan for a broader rollout of TalisMann and StimTrial in early 2026.
• Continue settlement discussions for the consolidated derivative shareholder lawsuits, with the next status update due to the Court on August 25, 2025.
• Evaluate the impact of the 'One Big Beautiful Bill Act' (OBBBA) tax legislation, with its effects to be reflected in the third quarter of 2025 financial statements.
• Potentially receive earn-out payments from the Advanced Rehabilitation Business divestiture based on 2025 and 2026 fiscal year sales.
• Continue to comply with financial covenants under the 2025 Credit Agreement, including maintaining a maximum consolidated total net leverage ratio and a minimum interest coverage ratio.

Key Dates

Recommendation

The company's return to profitability and positive EPS for the quarter and six-month period is a significant positive development, indicating improved financial health. The successful refinancing of debt, extending maturity and reducing interest costs, enhances financial stability. Furthermore, the FDA clearances for new PNS products represent a strategic expansion into a high-growth market segment, offering future revenue potential. While overall net sales declined, this was largely influenced by the strategic divestiture of a non-core business, which is a positive long-term move. The ongoing derivative lawsuits present a lingering risk, but the company's proactive management of these issues and its focus on core, innovative products suggest a stable to improving outlook. A 'hold' recommendation is appropriate as the company navigates this transition, with potential for 'buy' if future sales growth materializes and legal risks subside.

Keywords

Medical Devices, Musculoskeletal, Pain Management, Surgical Solutions, Orthopedics, Biotechnology, FDA Clearance, Peripheral Nerve Stimulation, Bone Growth Stimulators, Hyaluronic Acid, SEC Filing, 10-Q, Financial Results, Debt Refinancing, Divestiture